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Background
The deoxycytidine analog KP1212, and its prodrug
KP1461, are prototypes of a new class of antiretroviral
drugs designed to increase viral mutation rates, with the
goal of eventually causing the collapse of the viral popu-
lation. KP1212 will diminish or extinguish HIV-1 repli-
cation in cell culture, and has had very good safety
profiles in clinical trials. Here we present an extensive
analysis of viral sequences from patients from the first
“mechanism validation” phase II clinical trial in which
“salvage” patients received 1600 mg of drug twice per
d a yf o r1 2 4d a y s .T h eP h a s eI I as t u d yd i dn o td e m o n -
strate significant diminution of viral load. This was not
unexpected as prior cell culture studies showed little
change in viral titer prior to population collapse [1]. In
the present work we sought to identify a subclinical
impact of KP1461 therapy [2].
Materials and methods
We performed direct gene sequencing of a very large
number (>100) of sequences derived from individual
HIV-1 RNA templates, after 0, 56 and 124 days of ther-
apy from 10 treated and 10 untreated individuals. NMR
studies were performed to identify tautomeric forms of
the drug.
Results
Private mutations, those not found in multiple viruses,
were similar in treated and control individuals at day 0
(p=0.28), but were increased in treated individuals after
56 (p=0.02) and 124 (p=0.001) days of drug treatment.
Furthermore, the spectrum of mutations observed in the
treated group was distinct from that of the controls,
with an excess of A to G and G to A mutations
(p=0.01), and to a lesser extent T to C and C to T
mutations (p=0.09), in the treated group. Tautomeric
forms of the drug were detected that are predicted to
result in a substantial number of misincorporation
events during DNA synthesis.
Conclusions
The predicted mechanism of action of the drug (transi-
tion mutations with a bias toward A<>G) was demon-
strated in vivo. The observed increase in mutations in
treated patients and the chemical properties of the new
drug support a new mechanism of action by a novel
antiretroviral therapy in humans.
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